TAXUS IV is a randomized, double-blind pivotal trial enrolling 1,314 patients at 73 sites in the United States, assessing the safety and efficacy of the Company's slow-release formulation TAXUS® Express™ paclitaxel-eluting coronary stent system, now in its third follow up year. The TAXUS IV study, which met its primary endpoint of nine-month target vessel revascularization, has supported the safety, efficacy and durability of the TAXUS system across a broad range of complex patients.
"This impressive collection of analyses of the TAXUS IV data expands our understanding of the use of the TAXUS Express system in patient subsets and will assist our ongoing current and future research," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "We were particularly pleased that one of the articles concluded that site-specific delivery of paclitaxel is highly effective in reducing restenosis in patients with diabetes. We are honored that these TAXUS IV analyses are the focus of the first special issue in such a respected publication. It is a fitting tribute to the rigor of the TAXUS clinical program and our commitment to advancing the field."
The TAXUS IV articles published in the April 19 JACC are a collection of secondary analyses including the following:
To view abstracts of these articles, please visit the following website and scroll down to "Current Table of Contents": www.cardiosource.com/journalsbooks/journals/journal?sdid=4884&
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies, intellectual property, and other factors described in the Company's filings with the Securities and Exchange Commission.